Intabio introduces Blaze for biotherapeutics

Intabio launches their Blaze System in the hopes of accelerating biotherapeutic development

Register for free to listen to this article
Listen with Speechify
NEWARK, Calif.—Intabio Inc., a developer of analytical solutions, announced today that the company is now making their Blaze system commercially available. Blaze reportedly addresses a critical bottleneck for biopharmaceutical developers by quickly identifying unwanted structural modifications in intact biotherapeutic proteins. This capacity will enable scientists to make faster, more informed decisions while maintaining the highest product quality.
“The need to shorten drug development timelines has never been clearer than today,” said Lena Wu, Ph.D., co-founder and chief executive officer of Intabio. “We have collaborated with many of the world’s leading Biopharma development groups and mass spectrometry companies to directly address that need. With Blaze, crucial drug development decisions can be made months earlier.”
Intabio’s Blaze system couples two gold-standard analytical techniques — imaged capillary isoelectric focusing (iCIEF) and high-resolution mass spectrometry (MS) — into a single 15-minute assay with 100 times the throughput of traditional workflows. Microfluidic iCIEF separations of intact protein charge variants are performed by Blaze’s microchip-based cartridge, which uses 280-nm imaging for relative quantitation of charge variant peaks. Following iCIEF separation, each peak is introduced into an adjacent MS system for mass determination.
Biotherapeutic developers can quickly monitor multiple critical quality attributes directly on intact proteins — an important capability, when faced with large numbers of samples and tight timelines. Key Blaze applications include cell line development, bioprocess optimization and forced degradation studies.
“The Blaze technology promises to provide extremely rapid and comprehensive protein characterization earlier in bioprocess development with less analytical development time and much less material. Blaze will enable shorter development times to get high quality biotherapeutics to the clinic faster,” noted Intabio early access customer John Teare, Ph.D., vice president and cofounder of Coagulant Therapeutics Corp.
Blaze systems feature a new version of Protein Metrics’ Byos software suite customized for Blaze iCIEF-MS data analysis. The software was developed under the Intabio-Protein Metrics strategic partnership, which was announced earlier this year. Currently, Blaze systems can be interfaced with SCIEX TripleTOF 6600 and Thermo Fisher Q Exactive Plus high-resolution MS systems. Compatibility with additional MS systems is slated for release in 2021. The Blaze system is available for customer shipments in North America, beginning in late 2020.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue